Bioscience Today

30/07/2026

Turning Drug Resistance into a Therapeutic Opportunity in Sarcoma https://www.biosciencetoday.co.uk/turning-drug-resistance-into-a-therapeutic-opportunity-in-sarcoma/

Drug resistance remains one of the greatest challenges in cancer treatment. While many therapies initially succeed in slowing tumour growth, cancer cells can adapt over time, rendering previously effective treatments ineffective (1). For patients with advanced soft tissue sarcoma, the development of...

30/07/2026

Analysis of 65,000+ trials and 350,000+ sites show thousands of studies affected, with Phase III trials most exposed.

Full story: https://www.biosciencetoday.co.uk/middle-east-disruption-is-affecting-global-clinical-trials/

Analysis of 65,000+ trials and 350,000+ sites show thousands of studies affected, with Phase III trials most exposed. Analysis of 65,061 globally recruiting clinical trials across 186 countries has found that 4,361 studies – equivalent to 6.7% of all active trials – were impacted by disruption i...

29/07/2026

Théo Boyer, project manager at Indero, explores how novel methodologies could influence the collection of biological data in future clinical research.

Read more: https://www.biosciencetoday.co.uk/beyond-biopsies-new-methods-of-collecting-data-for-dermatology-research/

Théo Boyer, project manager at Indero, explores how novel methodologies could influence the collection of biological data in future clinical research. Dermatology trials frequently rely on blood draws and skin biopsies to evaluate inflammatory pathways, pharmacodynamic activity and drug exposure. W...

28/07/2026

Researchers at the Manchester Institute of Biotechnology (MIB) have used engineering biology to dramatically simplify how Lenacapavir is manufactured.

Full story: https://www.biosciencetoday.co.uk/scientists-develop-cheaper-more-sustainable-way-to-manufacture-hiv-drug/

With financial support from the Gates Foundation, researchers at the Manchester Institute of Biotechnology (MIB) have used engineering biology – an emerging technology that uses nature’s own processes to manufacture everyday chemicals and materials – to dramatically simplify how Lenacapavir is...

27/07/2026

The Pistoia Alliance calls for funding and expertise for the next phase of its social media project, marking its first direct engagement with oncology, rare disease and cardiology patients.

Read more: https://www.biosciencetoday.co.uk/first-best-practice-framework-for-ethical-social-media-use-in-drug-development/

The Pistoia Alliance calls for funding and expertise for the next phase of its social media project, marking its first direct engagement with oncology, rare disease and cardiology patients. The Alliance, a global, not-for-profit alliance advancing collaboration in life sciences R&D, is launching new...

24/07/2026

Myomaker Bio is set to transform the drug testing market with the development of advanced, lab-grown human muscle.

Full story: https://www.biosciencetoday.co.uk/uk-biotech-launches-world-first-lab-grown-human-muscle-platform-to-transform-drug-testing/

24/07/2026

A significant advance has been made in the fight against malaria with a promising new potential target for drug discovery.

Read more: https://www.biosciencetoday.co.uk/potential-new-route-for-antimalarial-drug-design/

A significant advance has been made in the fight against malaria with a promising new potential target for drug discovery. The findings – made by researchers from the Universities of Bath and Leeds – provide a powerful new framework for designing more effective antimalarial drugs with fewer side...

23/07/2026

Well-characterised biospecimens assist development of cancer immunotherapies https://www.biosciencetoday.co.uk/well-characterised-biospecimens-assist-development-of-cancer-immunotherapies/

Amsbio report how its biospecimens were used in a large-scale immuno-oncology study analysing Fibroblast Activation protein (FAP) expression across 23 tumour types, contributing to new insights into biomarker development for cancer immunotherapies. Scientists at Roche Pharma Research used both immun...

23/07/2026

Aston Institute for Membrane Excellence (AIME) has won a £438,674 Research Project Grant from the Leverhulme Trust to carry out fundamental research into how membrane proteins fold correctly.

Read more: https://www.biosciencetoday.co.uk/439000-leverhulme-trust-grant-to-research-membrane-protein-folding/